Clinical trial No longer in our active list Phase 3 Interventional Ages 18 to 99

Maridebart cafraglutide versus placebo for adults with obstructive sleep apnea who are overweight or obese and not using PAP

Official title: A Phase 3 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Maridebart Cafraglutide in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure Therapy and Living With Overweight or Obesity (MARITIME-OSA-2)

Run by Amgen · NCT07226765 · Data updated 2026-05-14

This study is no longer in our active list. It may have stopped recruiting or finished. The details below are as of 2026-05-14 and are kept for reference. Check ClinicalTrials.gov for its current status, or see similar studies below.

This study will test whether maridebart cafraglutide helps adults with obstructive sleep apnea who are overweight or obese and not using PAP therapy, compared with placebo over 52 weeks.

Quick facts

PhasePhase 3
Study typeInterventional
Ages18 Years to 99 Years
SexAll
Enrollment250 (estimated)
SponsorAmgen
Industry-sponsored
Locations42 sites (Northridge, California and 41 other locations)
Trial IDNCT07226765 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Adults with moderate-to-severe OSA (AHI ≥15) who have BMI ≥27 kg/m2, have tried weight loss, and are not using or planning to use PAP therapy are the intended participants.

Probably not a fit

People with predominant central apnea (≥50% central events), Cheyne–Stokes respiration, active PAP or oral appliance treatment, prior or planned upper airway surgery, or significant craniofacial abnormalities are unlikely to benefit from this study treatment.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 3, randomized, placebo-controlled trial comparing maridebart cafraglutide to placebo over 52 weeks in adults with obstructive sleep apnea who are not on PAP therapy. Eligible participants must have an apnea–hypopnea index (AHI) ≥15 on polysomnography and a BMI ≥27 kg/m2, with a history of at least one unsuccessful weight-loss attempt. Participants are randomized to receive maridebart cafraglutide or matching placebo and are monitored periodically for changes in OSA severity, body weight, and safety outcomes. Study visits and testing (including baseline and follow-up PSG) occur at clinical sites in California and Florida.

Why it matters

Potential benefit: If successful, the drug could reduce OSA severity and symptoms by promoting weight loss and airway improvement, offering a non‑PAP treatment option for patients unwilling or unable to use PAP.

How similar studies have gone: Other weight-loss drugs, particularly GLP-1 receptor agonists, have produced significant weight loss and modest improvements in OSA in smaller studies, but large phase 3 results specifically targeting OSA remain limited.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants must have an AHI of 15 or higher on polysomnography (PSG) at Day 1 before randomization.
* Body Mass Index (BMI) of 27 kg/m\^2 or more at the time of screening.
* History of at least one unsuccessful attempt at weight loss through diet and exercise.
* Participants must not have used PAP therapy for at least 4 weeks before screening, are unwilling/unable to use PAP, and do not plan to use PAP therapy during the study.

Exclusion Criteria:

* Individuals who have had any previous or planned upper airway surgery for sleep apnea or major ear, nose, or throat surgery.
* Those with significant craniofacial abnormalities that may affect breathing at screening.
* Participants diagnosed with Central Apnea with a percentage of central apneas/hypopneas of 50% or more, or those diagnosed with Cheyne Stokes Respiration.
* Active device treatment of OSA (eg, PAP, oral appliances), or other treatments, that in the opinion of the investigator, may interfere with study outcomes, unless willing to stop treatment at screening and throughout the study.
* Individuals with respiratory diseases like obesity hypoventilation syndrome or daytime hypercapnia, neuromuscular diseases or other conditions that could interfere with the trial results, according to the investigator's opinion.

Where it's running

  • Valley Clinical Trials
    Northridge, California, United States
    Recruiting
  • Peninsula Research Associates
    Rolling Hills Estates, California, United States
    Recruiting
  • Teradan Clinical Trials
    Brandon, Florida, United States
    Recruiting
  • Destiny Research Center
    Palmetto Bay, Florida, United States
    Recruiting
  • Clinical Research Center Of Florida
    Pompano Beach, Florida, United States
    Recruiting
  • NeuroTrials Research
    Atlanta, Georgia, United States
    Recruiting
Show 36 more locations
  • Basil Clinical
    Laurelton, New York, United States
    Recruiting
  • Monroe Biomedical Research
    Monroe, North Carolina, United States
    Recruiting
  • CTI Clinical Research Center
    Cincinnati, Ohio, United States
    Recruiting
  • FutureSearch Trials of Neurology
    Austin, Texas, United States
    Recruiting
  • Epic Medical Research - DeSoto
    DeSoto, Texas, United States
    Recruiting
  • Sleep Therapy & Research Center
    San Antonio, Texas, United States
    Recruiting
  • Northwest Clinical Research Center
    Bellevue, Washington, United States
    Recruiting
  • Woolcock Institute of Medical Research
    Macquarie Park, New South Wales, Australia
    Recruiting
  • Royal Brisbane and Womens Hospital
    Herston, Queensland, Australia
    Recruiting
  • Monash Medical Centre
    Clayton, Victoria, Australia
    Recruiting
  • Nucleo de Pesquisa do Rio Grande do Sul
    Porto Alegre, Rio Grande do Sul, Brazil
    Recruiting
  • CPQuali Pesquisa Clinica Ltda
    São Paulo, São Paulo, Brazil
    Recruiting
  • Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo Hcfmusp
    São Paulo, São Paulo, Brazil
    Recruiting
  • CaRe Clinic
    Calgary, Alberta, Canada
    Recruiting
  • Aggarwal and Associates Ltd
    Brampton, Ontario, Canada
    Recruiting
  • Wharton Medical Clinic
    Hamilton, Ontario, Canada
    Recruiting
  • Nemocnice Rudolfa a Stefanie Benesov as
    Benesov U Prahy, Czechia
    Recruiting
  • Fakultni nemocnice Brno
    Brno, Czechia
    Recruiting
  • Cerebrovaskularni poradna sro
    Ostrava - Poruba, Czechia
    Recruiting
  • Advanced Sleep Research
    Berlin, Germany
    Recruiting
  • InnoDiab Forschung
    Essen, Germany
    Recruiting
  • Diabeteszentrum Hamburg West
    Hamburg, Germany
    Recruiting
  • Siteworks - Zentrum fuer klinische Studien Hannover
    Hanover, Germany
    Recruiting
  • Siteworks - Zentrum fuer klinische Studien Karlsruhe
    Karlsruhe, Germany
    Recruiting
  • Red-Institut GmbH
    Oldenburg, Germany
    Recruiting
  • Saiseikai Futsukaichi Hospital
    Chikushino-shi, Fukuoka, Japan
    Recruiting
  • Fukuoka University Hospital
    Fukuoka, Fukuoka, Japan
    Recruiting
  • Sleep and Mental Clinic-Kitahiroshima
    Kitahiroshima-shi, Hokkaido, Japan
    Recruiting
  • Kuwamizu Hospital
    Kumamoto, Kumamoto, Japan
    Recruiting
  • Nakamura Clinic
    Urasoe-shi, Okinawa, Japan
    Recruiting
  • Gokeikai Osaka Kaisei Hospital
    Osaka, Osaka, Japan
    Recruiting
  • Narodowy Instytut Kardiologii Stefana Kardynala Wyszynskiego Panstwowy Instytut Badawczy
    Warsaw, Poland
    Recruiting
  • Centro Medico Teknon
    Barcelona, Catalonia, Spain
    Recruiting
  • Hospital Universitari Vall d Hebron
    Barcelona, Catalonia, Spain
    Recruiting
  • Hospital Medico Quirurgico San Rafael
    A Coruña, Galicia, Spain
    Recruiting
  • Hospital Universitario 12 de Octubre
    Madrid, Spain
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.